Real-world Comparative Effectiveness in Patients with Asthma Newly Initiating Fluticasone Furoate/Vilanterol or Budesonide/Formoterol: A United Kingdom General Practice Cohort Study
Patients who continued initiation treatment for a year without interruption had reduced exacerbation rates with FF/VI versus BUD/FOR. The FF/VI group also had reduced treatment discontinuation and OCS use.
Authors
- Christian Domingo (ORCID: https://orcid.org/0000-0001-8358-773X)
- Inés Palomares
- Ashley Woodcock (ORCID: https://orcid.org/0000-0002-5428-8578)
- Giorgio Walter Canonica (ORCID: https://orcid.org/0000-0001-8467-2557)
- Theo Tritton
- Alexander C. Ford (ORCID: https://orcid.org/0000-0001-6371-4359)
- Rosie Hulme
- John Blakey (ORCID: https://orcid.org/0000-0003-2551-8984)
- Sanchayita Sadhu
- Arunangshu Biswas
- Arnaud Bourdin
- Manish Verma (ORCID: https://orcid.org/0000-0002-8877-235X)
Institutions
- Universitat Autònoma de Barcelona (ES)
- Humanitas University (IT)
- Inserm (FR)
- Université de Montpellier (FR)
- Curtin University (AU)
- Manchester Academic Health Science Centre (GB)
- Sir Charles Gairdner Hospital (AU)
- Adelphi Group (United Kingdom) (GB)
- Manchester University NHS Foundation Trust (GB)
- GlaxoSmithKline (India) (IN)
- Madrid Health Service (ES)
- Institute of Research and Innovation Parc Tauli (ES)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Pulmonary Therapy
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1007/s41030-025-00313-2
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00